Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep's Potential Across Gastrointestinal Tumors
Penny Stock Oncolytics Biotech Says Colorecatal Cancer Drug's Durability Tops Historical Benchmarks
Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer
Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study
Oncolytics Could Re-Rate As Pelareorep Focuses On Registrational Paths
Financial Comparison: Erasca (NASDAQ:ERAS) vs. Oncolytics Biotech (NASDAQ:ONCY)
Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer
Oncolytics Biotech Inc. (NASDAQ:ONCY) Receives Consensus Rating of “Moderate Buy” from Analysts
Oncolytics Biotech® Completes Domicile Change to the United States
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026
Oncolytics Biotech® Launches Randomized Colorectal Cancer Study
Oncolytics Biotech (ONCY) Expected to Announce Earnings on Friday
Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
Oncolytics Biotech (NASDAQ:ONCY) Trading 1.3% Higher – Here’s Why
$207B Market Shift: The Race for Fast Track Approval in Oncology
Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer
$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium
Oncolytics Biotech® Announces Results of Special Meeting of Shareholders
Oncolytics Biotech Inc. (ONCY) Shareholder/Analyst Call Prepared Remarks Transcript
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff
Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer
Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada
Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings
Oncolytics Biotech® Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen O'Reilly, Dr. Neil Segal, and Dr. Van Morris
Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer
Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada
Oncolytics Biotech (ONCY) Loses 8.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Oncolytics Biotech® Provides Update on Special Meeting of Shareholders
All You Need to Know About Oncolytics Biotech (ONCY) Rating Upgrade to Buy
Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer
Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care
Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada
Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study
Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion
Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions
Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors
Oncolytics Biotech® Announces Upcoming Investor Conferences in September
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep
Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange
Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results
Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End
Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential
Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules
Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types
Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers
Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies
Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy